Centers for Medicare & Medicaid Services acting chief Andy Slavitt admonished pharma companies like Mylan (NSDQ:MYL) over unsustainable price increases before the Biopharma Congress in Washington D.C. last week. Mylan came under fire this year after reports showed that the Canonsburg, Penn.-based company raised the price of its emergency allergy epinephrine injector by 500% since it acquired the product in 2007 […]
Teva Pharmaceuticals
Mylan, Teva crash as DOJ could file charges by end of year
The U.S. Justice Dept. could reportedly file charges in its generic-drug pricing probe into companies including Mylan Pharmaceuticals (NSDQ:MYL) and Teva Pharmaceuticals (NYSE:TEVA) by the end of year. The department is examining whether the generic drug makers colluded on drug pricing, Bloomberg reported yesterday. The news source said that Mylan and Teva have disclosed subpoenas and are cooperating […]
Mylan CEO testifies before Senate about EpiPen pricing
Mylan CEO Heather Bresch testified before Senate yesterday after the Oversight and Government Reform Committee expressed concerns about the company’s price increases of its epinephrine auto-injector. Since Mylan (NSDQ:MYL) acquired the EpiPen from Merck in 2007 it has raised the price 17 times, from $100 in 2008 to nearly $600 today – a price increase of […]
Innovation & investment needed in drug delivery tech
When Menashe Levy was working on his Ph.D. from the Hebrew University of Jerusalem in the mid-80s, he encountered the very first renderings of innovation in drug delivery: controlled, sustained release of medicine. Now, as the vice president and CTO in Global R&D at Teva Pharmaceuticals, he looks towards the future of drug delivery: the […]
FDA approves Bayer’s Kyleena IUD
Bayer (ETR:BAYN) said yesterday that it won FDA approval for its hormonal contraceptive device, Kyleena, to prevent pregnancy for up to 5 years. The German company said the long-acting reversible contraceptive (LARC) is due to hit the market next month. LARCs are an increasingly popular form of birth control, including intrauterine devices like Kyleena. Bayer’s […]
Teva plans competitor for Mylan’s EpiPen
Teva Pharmaceutical (NYSE:TEVA) said last week that it hopes to win U.S. approval for its version of Mylan‘s (NSDQ:MYL) EpiPen by late 2017 or early 2018. Mylan’s EpiPen holds an estimated 94% market share in the U.S.; an alternate device from Teva could threaten the product’s dominance. Teva’s application for its epinephrine injector has been […]
Philips, Teva invest in Israeli medtech
Reuters — Teva Pharmaceuticals (NYSE:TEVA) and Royal Philips (NYSE:PHG) are together investing up to 100 million shekels ($26.5 million) over 8 years in medical device and health technology startups in Israel. The joint venture, called Sanara Ventures, said today it had already invested in 2 companies: Kaleidoscope Medical, which developed a system for X-ray radiation shielding during catheterization procedures; […]
Teva Pharmaceutical and Microchips Biotech ink $35m deal for drug-device combo
Teva Pharmaceutical (NYSE:TEVA) and Microchips Biotech said they inked a $35 million co-development deal to explore using Microchips’ implantable drug delivery device with Teva’s line of drugs. The wireless Microchips device can store 100s of doses for months or even years and be programmed to release the drug at precise times or schedules, the companies said yesterday. “The […]
Medtronic, Johnson & Johnson store billions in cash in overseas subsidiaries | Medtech Wall Street news for the week of June 9, 2014
Philips, Teva ink Israeli medtech incubator JV
SpinalMotion closes 4th tranche of $15M round | Wall Street Beat
SpinalMotion closed the final tranche of a $15 million funding round that began in June 2011, according to a regulatory filing.
The Mountain View, Calif.-based medical device company raised a total of $15.1 million in the offering of debt, options and warrants from 15 unnamed investors, according to the filing.